Evidence map›Paper›PMID 39623059›Full record

ArticleScientific reports2024

Elevated glucagon and postprandial hyperglycemia in fatty liver indicate early glucose intolerance in metabolic dysfunction associated steatotic liver disease.

Rieko Oikawa, Yumiko Nakanishi, Keiji Fujimoto, Asako Wakasa, Mizuho Iwadare, Haruka Kawanami Iwao, Ryoko Ishida, Kunimitsu Iwai

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Glucose curve morphology and peak time as biomarkers of metabolic health.American journal of physiology. Endocrinology and metabolism · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rieko OikawaHealth Evaluation Center, Kanazawa Medical University, 1-1, daigaku, uchinadamachi, kahokugun, Ishikawa, 9200293, Japan. roikawa@kanazawa-med.ac.jp.
Yumiko NakanishiHealth Evaluation Center, Kanazawa Medical University, 1-1, daigaku, uchinadamachi, kahokugun, Ishikawa, 9200293, Japan.
Keiji FujimotoDepartment of Nephrology, Kanazawa Medical University, 1-1, daigaku, uchinadamachi, kahokugun, Ishikawa, 9200293, Japan.
Asako WakasaHealth Evaluation Center, Kanazawa Medical University, 1-1, daigaku, uchinadamachi, kahokugun, Ishikawa, 9200293, Japan.
Mizuho IwadareHealth Evaluation Center, Kanazawa Medical University, 1-1, daigaku, uchinadamachi, kahokugun, Ishikawa, 9200293, Japan.
Haruka Kawanami IwaoHealth Evaluation Center, Kanazawa Medical University, 1-1, daigaku, uchinadamachi, kahokugun, Ishikawa, 9200293, Japan.
Ryoko IshidaHealth Evaluation Center, Kanazawa Medical University, 1-1, daigaku, uchinadamachi, kahokugun, Ishikawa, 9200293, Japan.
Kunimitsu IwaiHealth Evaluation Center, Kanazawa Medical University, 1-1, daigaku, uchinadamachi, kahokugun, Ishikawa, 9200293, Japan.

Funding

JSPS KAKENHI JP21K10483
6 · The paper itself

Abstract

In Japan, fatty liver cases with elevated body mass index are increasing. Because of being non-malignant, these are often neglected unless accompanied by diabetes. This study investigated the risk of glucose intolerance in individuals with non-alcoholic fatty liver. We included 165 men (mean age 56.3 years; range 29-75 years) who underwent an overnight 2-day physical examination at our Health Evaluation Center. All patients underwent abdominal ultrasonography to examine fatty liver. Fasting blood glucose and 75-g glucose tolerance test (OGTT) were conducted. alanine aminotransferase (ALT) (p < 0.01) and triglyceride (p < 0.001) levels were significantly higher in the fatty liver group (FL) than in the non-fatty liver group. HbA1c, fasting blood glucose, and blood glucose level at OGTT (0 and 30 min) did not show significant differences. In the FL, OGTT was significantly elevated at 60 min(p < 0.01)and 120 min (p < 0.001), insulin level was significantly elevated at 0 and 30 min (p < 0.001), and glucagon level was significantly elevated at 0 min (p < 0.05) and 30 min (p < 0.01), with no significant differences between the groups at 60 and 120 min. This is the first study to demonstrate elevated glucagon levels after OGTT. Metabolic dysfunction-associated steatotic liver disease (MASLD) requires treatment for insulin resistance with glucagon dysregulation likely associated with its pathogenesis.

Indexed as

Blood GlucoseGlucagonGlucose IntoleranceHyperglycemiaAdultAgedFatty LiverGlucose Tolerance TestHumansInsulinMaleMiddle AgedNon-alcoholic Fatty Liver DiseasePostprandial PeriodBlood GlucoseGlucagonInsulinA 75 g oral tolerance testGlucagonMAFLD

Identifiers

PMID39623059
PMCPMC11612171

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.